Can systemic lupus erythematosus (SLE) cause amyloid sarcoidosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Systemic Lupus Erythematosus and Amyloidosis

Systemic lupus erythematosus (SLE) can rarely be associated with AA amyloidosis, but there is no established connection between SLE and amyloid sarcoidosis specifically.

Relationship Between SLE and Amyloidosis

  • AA amyloidosis is a rare complication of SLE that has been documented in only a small number of case reports 1, 2, 3, 4
  • AA amyloidosis in SLE typically occurs secondary to long-standing inflammation, which can lead to the deposition of amyloid A protein in various organs 1
  • When amyloidosis occurs in SLE patients, it most commonly manifests as renal involvement with proteinuria, which should be considered in the differential diagnosis of proteinuria in SLE patients 1
  • Systemic inflammation may predispose to the development of amyloidosis, requiring monitoring through proteinuria and microalbuminuria testing 5

SLE and Sarcoidosis Connection

  • The coexistence of sarcoidosis and SLE in the same patient has been uncommonly reported in the literature 6
  • A literature review identified only 25 published cases of concurrent SLE and sarcoidosis, suggesting this combination is rare but possibly underreported 6
  • When both conditions coexist, sarcoidosis typically presents with mild pulmonary symptoms while SLE manifestations are highly variable 6
  • There is no established connection between SLE and amyloid sarcoidosis specifically in the medical literature 6

Clinical Implications and Monitoring

  • SLE patients should be monitored for systemic inflammation using markers including peripheral neutrophilia, CRP, and ESR 5, 7
  • Patients with long-standing SLE should be evaluated for potential development of amyloidosis through regular monitoring of proteinuria and microalbuminuria 5
  • In SLE patients with unexplained proteinuria, amyloidosis should be considered in the differential diagnosis 1
  • SLE patients with cutaneous manifestations, cytopenia, renal involvement, and/or positivity for ANA and anti-dsDNA antibodies who develop pulmonary symptoms should be evaluated for potential concurrent sarcoidosis 6

Treatment Considerations

  • When SLE and sarcoidosis coexist, treatment typically includes oral glucocorticoids, hydroxychloroquine, and conventional immunosuppressive drugs 6
  • In severe cases of concurrent SLE and sarcoidosis, cyclophosphamide may be considered 6
  • Controlling systemic inflammation in SLE is crucial to potentially prevent the development of secondary amyloidosis 1, 4
  • Regular monitoring of organ function is essential in SLE patients, particularly those with long-standing disease, to detect complications such as amyloidosis early 7

Diagnostic Approach

  • Histological examination with Congo red staining is necessary to confirm amyloidosis in SLE patients 1, 2
  • Permanganate sensitivity testing can help identify amyloid A protein in tissue samples 1
  • Elevated serum amyloid A protein levels may be present in SLE patients who develop AA amyloidosis 1
  • For suspected sarcoidosis in SLE patients, histological evidence of non-caseating granulomas is required for diagnosis 6

References

Research

Amyloidosis in systemic lupus erythematosus.

The American journal of medicine, 1981

Research

Amyloid A amyloidosis and systemic lupus erythematosus.

Expert review of clinical immunology, 2007

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Systemic Lupus Erythematosus Clinical Manifestations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.